Skip to main content
Clinical Trials/CTRI/2014/03/004452
CTRI/2014/03/004452
Other
Phase 4

A Multicentric Prospective Observational Registry to evaluate safety, efficacy and cost effectiveness of using Bivalirudin in an Acute Coronary Syndrome (ACS) patient population undergoing percutaneous coronary intervention (PCI) in India.

Institute of Cardio Vascular Diseases0 sites1,500 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Acute Coronary Syndrome (ACS) patient population undergoing percutaneous coronary intervention
Sponsor
Institute of Cardio Vascular Diseases
Enrollment
1500
Status
Other
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
Institute of Cardio Vascular Diseases

Eligibility Criteria

Inclusion Criteria

  • Patient who can provide Informed Consent Document signature form for collection of data as approved by the ethics committee
  • Acute Coronary Syndrome (ACS) patient undergoing percutaneous coronary intervention (PCI) in India

Exclusion Criteria

  • Patients who cannot provide Data Access Consent signature form for collection of data
  • Allergy to bivalirudin or Aspirin, or known sensitivity to any component of the products
  • Active major bleeding
  • Noncardiac coexisting conditions that could limit life expectancy to less than 1 year
  • Known pregnancy or nursing mothers. Women of child\-bearing age will be screened for pregnancy and will have to adopt birth control measures till the duration of the study.
  • Treatment with Low Molecular Weight Heparin (LMWH) within 8 hours prior to the intervention
  • Warfarin MUST be discontinued prior to procedure, and the INR \<\=1\.5, or the PT \>15
  • Dabigatran MUST be discontinued 1 to 2 days (CrCl \>\=50 mL/min) or 3 to 5 days (CrCl \<50 mL/min) prior to procedure

Outcomes

Primary Outcomes

Not specified

Similar Trials